134 related articles for article (PubMed ID: 23197685)
1. Insulin-like growth factor-1 as a predictive biomarker for metastatic uveal melanoma in humans.
Frenkel S; Zloto O; Pe'er J; Barak V
Invest Ophthalmol Vis Sci; 2013 Jan; 54(1):490-3. PubMed ID: 23197685
[TBL] [Abstract][Full Text] [Related]
2. Using the direct-injection model of early uveal melanoma hepatic metastasis to identify TPS as a potentially useful serum biomarker.
Barak V; Frenkel S; Valyi-Nagy K; Leach L; Apushkin MA; Lin AY; Kalickman I; Baumann NA; Pe'er J; Maniotis AJ; Folberg R
Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4399-402. PubMed ID: 17898257
[TBL] [Abstract][Full Text] [Related]
3. VEGF as a biomarker for metastatic uveal melanoma in humans.
Barak V; Pe'er J; Kalickman I; Frenkel S
Curr Eye Res; 2011 Apr; 36(4):386-90. PubMed ID: 21284506
[TBL] [Abstract][Full Text] [Related]
4. Osteopontin as a serologic marker for metastatic uveal melanoma: results of a pilot study.
Reiniger IW; Wolf A; Welge-Lüssen U; Mueller AJ; Kampik A; Schaller UC
Am J Ophthalmol; 2007 Apr; 143(4):705-7. PubMed ID: 17386288
[TBL] [Abstract][Full Text] [Related]
5. c-Met, epidermal growth factor receptor, and insulin-like growth factor-1 receptor are important for growth in uveal melanoma and independently contribute to migration and metastatic potential.
Wu X; Zhou J; Rogers AM; Jänne PA; Benedettini E; Loda M; Hodi FS
Melanoma Res; 2012 Apr; 22(2):123-32. PubMed ID: 22343486
[TBL] [Abstract][Full Text] [Related]
6. Osteopontin and 'melanoma inhibitory activity': comparison of two serological tumor markers in metastatic uveal melanoma patients.
Haritoglou I; Wolf A; Maier T; Haritoglou C; Hein R; Schaller UC
Ophthalmologica; 2009; 223(4):239-43. PubMed ID: 19270465
[TBL] [Abstract][Full Text] [Related]
7. The dynamics of serum tumor markers in predicting metastatic uveal melanoma (part 1).
Barak V; Kaiserman I; Frenkel S; Hendler K; Kalickman I; Pe'er J
Anticancer Res; 2011 Jan; 31(1):345-9. PubMed ID: 21273622
[TBL] [Abstract][Full Text] [Related]
8. Melanoma inhibitory activity: a novel serum marker for uveal melanoma.
Schaller UC; Bosserhoff AK; Neubauer AS; Buettner R; Kampik A; Mueller AJ
Melanoma Res; 2002 Dec; 12(6):593-9. PubMed ID: 12459649
[TBL] [Abstract][Full Text] [Related]
9. Insulin-like growth factor-1 receptor in uveal melanoma: a predictor for metastatic disease and a potential therapeutic target.
All-Ericsson C; Girnita L; Seregard S; Bartolazzi A; Jager MJ; Larsson O
Invest Ophthalmol Vis Sci; 2002 Jan; 43(1):1-8. PubMed ID: 11773005
[TBL] [Abstract][Full Text] [Related]
10. Serum markers to detect metastatic uveal melanoma.
Barak V; Frenkel S; Kalickman I; Maniotis AJ; Folberg R; Pe'er J
Anticancer Res; 2007; 27(4A):1897-900. PubMed ID: 17649791
[TBL] [Abstract][Full Text] [Related]
11. Osteopontin expression and serum levels in metastatic uveal melanoma: a pilot study.
Kadkol SS; Lin AY; Barak V; Kalickman I; Leach L; Valyi-Nagy K; Majumdar D; Setty S; Maniotis AJ; Folberg R; Pe'er J
Invest Ophthalmol Vis Sci; 2006 Mar; 47(3):802-6. PubMed ID: 16505010
[TBL] [Abstract][Full Text] [Related]
12. Liver function tests in metastatic uveal melanoma.
Kaiserman I; Amer R; Pe'er J
Am J Ophthalmol; 2004 Feb; 137(2):236-43. PubMed ID: 14962411
[TBL] [Abstract][Full Text] [Related]
13. Elevated blood β-2 microglobulin is associated with tumor monosomy-3 in patients with primary uveal melanoma.
Triozzi PL; Elson P; Aldrich W; Achberger S; Tubbs R; Biscotti CV; Singh AD
Melanoma Res; 2013 Feb; 23(1):1-7. PubMed ID: 23196330
[TBL] [Abstract][Full Text] [Related]
14. Prospective study of surveillance testing for metastasis in 100 high-risk uveal melanoma patients.
Piperno-Neumann S; Servois V; Mariani P; Plancher C; Lévy-Gabriel C; Lumbroso-Le Rouic L; Couturier J; Asselain B; Desjardins L; Cassoux N
J Fr Ophtalmol; 2015 Jun; 38(6):526-34. PubMed ID: 25978872
[TBL] [Abstract][Full Text] [Related]
15. sIL-2R- an Immuno-biomarker for Prediction of Metastases in Uveal Melanoma.
Barak V; Kalickman I; Pe'er J
Anticancer Res; 2022 Mar; 42(3):1447-1453. PubMed ID: 35220238
[TBL] [Abstract][Full Text] [Related]
16. Prognostic relevance of circulating tumor cells in metastatic uveal melanoma.
Schuster R; Bechrakis NE; Stroux A; Busse A; Schmittel A; Thiel E; Foerster MH; Keilholz U
Oncology; 2011; 80(1-2):57-62. PubMed ID: 21625180
[TBL] [Abstract][Full Text] [Related]
17. Correlation of clinicopathological parameters with HGF, c-Met, EGFR, and IGF-1R expression in uveal melanoma.
Topcu-Yilmaz P; Kiratli H; Saglam A; Söylemezoglu F; Hascelik G
Melanoma Res; 2010 Apr; 20(2):126-32. PubMed ID: 20061986
[TBL] [Abstract][Full Text] [Related]
18. Trends in liver function tests: a comparison with serum tumor markers in metastatic uveal melanoma (part 2).
Hendler K; Pe'er J; Kaiserman I; Baruch R; Kalickman I; Barak V; Frenkel S
Anticancer Res; 2011 Jan; 31(1):351-7. PubMed ID: 21273623
[TBL] [Abstract][Full Text] [Related]
19. Serum insulin-like growth factor is not elevated in patients with early B-cell chronic lymphocytic leukemia but is still a prognostic factor for disease progression.
Molica S; Vitelli G; Mirabelli R; Digiesu G; Giannarelli D; Cuneo A; Ribatti D; Vacca A
Eur J Haematol; 2006 Jan; 76(1):51-7. PubMed ID: 16343271
[TBL] [Abstract][Full Text] [Related]
20. Receptors for the liver synthesized growth factors IGF-1 and HGF/SF in uveal melanoma: intercorrelation and prognostic implications.
Economou MA; All-Ericsson C; Bykov V; Girnita L; Bartolazzi A; Larsson O; Seregard S
Acta Ophthalmol; 2008 Nov; 86 Thesis 4():20-5. PubMed ID: 19032678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
